Next, to determine the association of TOX expression and T cell clonality in early-stage CTCL, we evaluated the expression of TCRVβ22 and observed variation ranging from 14% to 75%. This evidence concerns the gene TOX and primary cutaneous T-cell non-Hodgkin lymphoma.